GRML (Greenland Mines) Beneish M-Score


GRML Greenland Mines Ltd GRML
12 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is Greenland Mines Beneish M-Score?

Greenland Mines does not have enough data to calculate Beneish M-Score.

Greenland Mines Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Greenland Mines's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenland Mines Beneish M-Score Chart

Greenland Mines Annual Data
Trend
Beneish M-Score

Greenland Mines Semi-Annual Data
Mar25 Mar26
Beneish M-Score 0.00 0.00

GRML vs SRGZ, RITE, DYNR: Beneish M-Score Comparison

For the Other Precious Metals & Mining subindustry, Greenland Mines's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenland Mines Beneish M-Score vs Metals & Mining Industry

For the Metals & Mining industry and Basic Materials sector, Greenland Mines's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Greenland Mines's Beneish M-Score falls into.


GRML
12GF Score
Greenland Mines Ltd GRML
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenland Mines Business Description

Address 1300 South Boulevard, Unit D, Charlotte, NC, USA, 28203
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
12GF Score

Get the complete analysis for GRML

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price